SYSTEMATIC REVIEW article

Front. Endocrinol., 24 March 2022

Sec. Obesity

Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.857930

Normal Weight Obesity and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis

  • 1. Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

  • 2. Center for Microsystems Technology, Imec & Ghent University, Zwijnaarde-Gent, Belgium

  • 3. Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran

  • 4. Department of Pediatrics, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

  • 5. Department of Nutrition, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

  • 6. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Article metrics

View details

94

Citations

28k

Views

10,8k

Downloads

Abstract

Background:

Obesity is one of the most significant causes of morbidity and mortality worldwide. Current studies suggest a new type of obesity, normal weight obesity (NWO), which is defined as having a normal body mass index (BMI), but a high-fat percentage increases the risk of cardiometabolic risk factors (CMRFs). This systematic review and meta-analysis aimed to pool the association between NWO with CMRFs.

Methods:

A systematic search of the literature in all available electronic databases, including Scopus, Web of Science, EMBASE, and PubMed, was performed until October 2021. All English studies that assessed the association of NWOs [compared to normal weight non-obese (NWNO)] and the CMRFs were included. Two investigators extracted data and performed a quality assessment. The heterogeneity between studies was assessed with I-squared and Cochran’s Q tests. Odds ratio (OR) was used as an effect size to pool the association of NWO with CMRFs.

Results:

Twenty-five articles that met the inclusion criteria entered the study. The total number of participants was 177,792, with an age range of 13 to 75 years. Most studies were conducted on the general population (adults) and were from China. The result of fixed-effect model meta-analysis indicated an increased odds of hyperglycemia (OR:1.50, 95%:1.23, 1.76), high TG (OR:1.90, 95% CH:1.44, 2.35), low HDL (OR: 1.28, 95% CI:1.06, 1.49) and diabetes (OR:1.39, 95% CI:1.30, 1.49). Moreover, the random effect meta-analysis showed that NWO increased the odds of dyslipidemia (OR:1.83, 95% CI:1.61, 20.4), HTN (OR:1.40, 95% CI:1.28, 1.51) and metabolic syndrome (OR:1.92, 95% CI:1.58, 2.26). Moreover, the mean of all CMRFs except plasma glucose in NWO subjects was statistically higher than NWNO subjects (p-value<0.05).

Conclusion:

The present study showed that NWO increased the odds of CMRFs. These findings indicate the inadequacy of the BMI measurement and the need for body fat assessment for a better obesity risk assessment.

Background

Obesity is one of the most significant causes of morbidity and mortality worldwide (1, 2). In literature, obesity is usually defined as a body mass index (BMI) above 30 Kg/m2 (2). The prevalence of obesity is increasing throughout the globe. This disease imposes a significant burden on the affected population and the health system. It is also considered a fulcrum of other conditions, such as cardiometabolic conditions, that arise from obesity and are the leading cause of death worldwide (13). Although the prevalence of these supposedly obesity-related complications (e.g., diabetes, hypertension, dyslipidemia, etc.) and cardiometabolic diseases is exceptionally higher among obese individuals, their prevalence has been increased in the past few decades, among the non-obese population (BMI under 30 Kg/m2) and even in those considered healthy based on their BMI levels (BMI between 18.5 to 24.9 Kg/m2) (46). This shows that BMI, long known as a great assessment tool, cannot determine an individual’s body composition, and fat percentage, lacking the adequate properties to identify those with a high body fat percentage or disproportionate body fat distribution (e.g. abdominal obesity) (7) Recent studies suggest the percentage of body fat is directly related to cardiometabolic and obesity-related conditions. This is a new type of obesity in which an individual with normal BMI levels is considered as obese based on their body composition and fat percentage (8, 9). Normal weight obesity (NWO) has different definitions based on the studies, population, and gender; however, it is usually defined as a body fat percentage above 30% (10). Due to the lifestyle changes, lack of proper physical activity and the use of processed food, the numbers of obese individuals are on the rise (11, 12); accordingly, the number of the normal weigh obese might be increasing; however, due to their normal BMI they will remain undiagnosed, and no proper preventive measure is taken until it is too late (13). Since there has been no new individual data or aggregated systematic reviews and meta-analyses on this relatively novel subject, we conducted this study to assess the cardiometabolic risk factors (CMRFs) and anthropometric measurements in the NWO individuals and compare them with the normal population. This study aims to give a realistic overview of the emerging obesity-related conditions so that health authorities can take proper action and implement appropriate preventive measures.

Methods

This study was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.

Search Strategy

We conducted a systematic search of the literature in all available electronic databases, including Scopus, Web of Science, EMBASE, and PubMed, until October 2021. The terms used for the search was “NWO”, “central obesity”,” high-fat percentage”, and their equivalent terms based on MesH terms. The search strategy is presented in the Supplementary Table 1. Moreover, one investigator conducted the search, and another investigator reviewed the search results.

Eligibility Criteria and Selection Study

All English studies that assessed anthropometric measurements and the CMRFs [BMI, lean body mass, body fat mass, waist, hip, plasma glucose level, total cholesterol, Homeostatic Model Assessment for Insulin Resistance (HOMA), low-density lipoprotein (LDL), High-density lipoprotein (HDL), Triglyceride (TG), Total cholesterol (TC), systolic blood pressure (SBP), diastolic blood pressure (DBP), hypertension (HTN)] among NWO individuals were included. All studies had to represent the target population and compare them with the normal-weight non-obese (NWNOs) individuals and adjust for possible confounders to be included in our study. Only the most recent studies were included in our research if multiple studies used the same data source. All definitions of NWO, Regardless of their variety (e.g. normal BMI with high body fat percentage, normal BMI with high waist circumference (central obesity), high waist to hip/height ratio and etc.) were included in this study.

After removing the duplicates using EndNote X7, two investigators independently assessed the titles, abstracts, and finally, the full texts of the remaining articles. In addition, hand searching was performed to find relevant studies from the reference list of the included articles. Any discrepancies were referred to the third investigator for resolution.

Data Extraction Strategy

Two investigators independently extracted the data using an electronic data extraction sheet. The extracted data included the name of the first author, the year of the study, sample size, sex, age (mean or range), NWO definition, CMRFs, Odds ratios (OR) or standard mean difference (SMD), and 95% confidence interval (CI) as an effect size of dichotomous and continuous data respectively. Two other investigators helped resolve any discrepancy.

Quality Assessment (QA)

The Newcastle-Ottawa Scale was used for the quality assessment of the included articles. This seven-item scale scores the selection, exposure (case-control study) and outcome (cohort study), and comparability of the studies. The total score, which is the sum of each item score, ranges from 0 to 9, with greater scores indicating lower bias risk. The scores were categorized as 0 to 4, 5 and 6, 7 to 9, meaning unsatisfactory, satisfactory, and good quality, respectively. All of the above steps were assessed independently by two investigators. Finally, any discrepancies were referred to the third investigator for resolution.

Statistical Analysis

The heterogeneity between the studies was assessed using the I-squared and Cochran’s Q tests if heterogeneity was statistically significant (P-value<0.1) (14). a random effect model was used; otherwise, a fixed model was applied. Odds Ratio (OR) and 95% confidence interval (CI) were used as an effect size of meta-analysis to pool the association of NWO with CMRFs as a dichotomous variable. We also calculated and pooled the standardized mean difference (SMD) as an effect size for NWO association with the means of CMRFs. Meta-analysis was done for outcomes that were reported in more than three studies. Sub-group analysis was performed for the CMRFs. Publication bias was assessed using Egger’s test for each CMRF; if publication bias was seen, sensitivity analysis was performed. STATA version 11 (Stata Corporation, College Station, Texas, USA) was used for the analysis.

Results

Search Results

From the 523 studies of the initial search, 270 were duplicates; thus, 253 articles were evaluated, and 201 were considered irrelevant based on the title and abstract. The remaining 52 articles’ full text was then assessed and evaluated for eligibility criteria, and 27 articles were excluded. Twenty-three articles met the inclusion criteria. Two studies with unadjusted data for potential confounders were included due to their exceptionally high, quality assessment score; however, these two studies were not included in the Quantitative synthesis. This process is illustrated in Figure 1.

Figure 1

Figure 1

Studies search and review flowchart.

General Characteristics

These studies were conducted worldwide (United States of America, Sweden, Korea, Colombia, West Indies, China, India, Iran, Japan, Iceland, Malaysia, Switzerland, Brazil, and Finland). The total number of participants was 177,792, with an age range of 13 to 75 years. These data, alongside other study characteristics, are presented in Table 1. Most of these studies were conducted on the general population (adults) and were from china (5 studies) and Korea (4 studies). With one study, Sweden, West Indies, India, Iran, Japan, Iceland, Malaysia, Switzerland, and Finland had the lowest number of studies. The largest sample size was from Japan with 117163 participants, and the smallest was from Iceland with 182 participants (4, 6, 8, 1536).. These general characteristics of included studies for NWO association with CMRFs are shown in Table 1.

Table 1

Author YearCountrysample sizeMean Age/Age RangeStudy PopulationDefinition of NWO* Q.A
TotalMFNWNONWO
Bellissimo 2019 (15)USA28963116264347Adults/general populationBF: 23% men, 30% women6
Berg 2015 (16)Sweden1471581890108026625-74Adults /general populationBF: 25% men , 38% women8
W. K. Cho 2015 (17)Korea1700888812126614413-18Adolescentsupper highest quartile (Q4) of age and sex specific Waist-to-height ratio8
M. Correa 2020 (18)Colombia135452882696139318-32Adults /general populationBF: 25.5% men , 38.9% women9
Ramsaran 2017 (19)West Indies236761601897418-32Adults /general populationBF: 23% men , 33% women6
A. García 2020 (20)Colombia1919955964103588413Children and AdolescentsBF: boys > 23.4%–28.3% and girls > 31.0%–34.1%7
H. He 2019 (21)China2654(–)(-)191672946.9 ± 1380Adults /general population BF: 21.4% men , 31.4% women9
A. Jia 2018 (22)China1529114921379999881771under 75Adults / general populationBF: ≥24% for men and ≥33% for women10
Kapoor 2020 (23)India114761952820036447.3 ± 7.5Adults /general populationBF: , ≥20.6% men, ≥33.4% women,9
Kim 2014 (24)Korea12217531369043382157544Adults /general populationBF: ≥20.6% men, ≥33.4% women8
Kim 2018 (25)Korea3949(–)(-)2213868(-)Adults /general populationBF: ≥23.1% men, ≥33.1% women6
Sohee Kim 2015 (26)Korea20781141937179528353.4Adults /general populationBF: ≥25.4 % men, ≥31.4 % women8
H. Zhao 2012 (27)China407(-)(-)(-)(-)(-)(-)BF: ≥25 % men, ≥35 % women5
Tayefi 2019 (28)Iran2439(–)(-)1311112847Adults /general populationBF: > 25%men, >30% women9
T. Shirasawa 2019 (8)Japan1171638248734676430551287740-64Adults /general populationWaist-to-height ratio ≥ 0.510
A. Romero 2010 (6)USA4116208920272054206241.3Adults /general populationBF: ≥23.1 % men, ≥33.3 % women8
A. S. Olafsdottir 2016 (29)Iceland18296861067617.7-18.9High-school students/ adolescentsBF: > 17.6% men , >31.6% women5
F. M. Moy 2015 (30)Malaysia858085851123740.47 ± 8.9Adults /teachers BF: >28.52%6
K. E. Martinez 2017 (31)USA3600(-)(-)1624288adultsAdults /general populationBF: 27.8 ± 0.2% men, 40.5 ± 0.2 % women5
P. Marques-Vidal 2010 (32)Switzerland230102301166717335-75Adults/general population whitesBF: ≥38%7
F. B. Madeira 2013 2013 (4)Brazil1222546676111111123-25young adultsBF: ≥23% men, ≥30% women10
P. J. Liu 2017 (33)China412041221419855.72Post menopause general population womenthird tertile of normal weight body fat6
C. C. N. Da Silva 2021 (34)Brazil7873464415534723-25Young adults>90th percentile body fat10

General Characteristics of included studies for association of NWO with CMRFs.

CMRFs, cardio-metabolic risk factors; M,male; F, female; NWNO, normal weight none obese; NWO, normal weight obese; BF, body fat (based on percentage); USA, United State; Q.A, quality assessment based on the Newcastle Ottawa scale (out of 10 points); * all NWOs had BMIs within normal range.

Qualitative Synthesis

The association of NWO with the means of CMRFs compared to NWNO in included studies is shown in Table 2 alongside their effect size. As illustrated, most anthropometric components among NWOs significantly differed from that of NWNOs with the most significant, regarding the fat mass [effect size: -1.9 95%.CI (-2.01_-1.8)]. The reported mean range of the associated cardiometabolic parameters are as follows, plasma glucose 81.96 to 95.7 mg/dL for NWNOs and 80.47 to 99.1 mg/dL for NWOs. Total cholesterol, 181.61 to 204.97 mg/dL for NWNOs and 189.61 to 216.55 mg/dL for NWOs, HOMA, 0.6 to 3.32 for NWNOs and 0.8 to 3.18 for NWOs, LDL, 105.3 to 121.8 mg/dL for NWNOs and 117.67 to 132.64 mg/dL for NWOs, HDL mg/dL, 42.09 to 72.7 mg/dL for NWNOs and 45.72 to 69.5 mg/dL for NWOs, TG, 76.72 to 116.03 mg/dL for NWNOs and 85.32 to 136.4 mg/dL for NWOs, SBP, 107.81 to 129 mmHg for NWNOs and 110.58 to 134 mmHg for NWOs, DBP, 71 to 80 mmHg for NWNOs and 72.1 to 85 mmHg for NWOs. As for anthropometrics, the mean ranges of lean mass were 40.21 to 57.5 kg in NWNOs and 39.9 to 57.4 kg in NWOs, waist, 59.12 to 84.4 cm for NWNOs and 63.94 to 89.9 in NWOs, hip 93.2 to 96.1 cm in NWNOs and 94.6 to 98.9 cm NWOs. Association of NWO with CMRFs as categorical data in included studies are shown in Table 3. As illustrated, most reported ORs are statistically significant. The greatest reported OR was of elevated waist circumference (WC) among NWOs [OR: 26.61 95%.CI (4.75-149.14)] and the odds of metabolic syndrome (MetS) among NWOs [OR:8.89 95%.CI (3.32-4.47)].

Table 2

Author, yearOutcomeNWNONWOEffect sizeAdjustment
MeanSDMeanSDSMD95% CI
Bellissimo, 2019 (15)Plasma glucose95.72493.126.20.1-0.39_0.59Sex, age and ethnicity
Plasma insulin2.72.53.63.2-0.3-0.79_0.19
TC193.947201.452.4-0.15-0.63_0.34
HOMA0.60.50.80.65-0.33-0.82_0.16
LDL105.341117.845.85-0.28-0.77_0.21
HDL72.71963.521.610.44-0.05_0.93
TG81.157101.262.22-0.33-0.82_0.16
SBP119.418118.120.30.07-0.42_0.55
DBP74.712.575.513.75-0.06-0.55_0.43
BMI23.94.5924.34.55-0.09-0.57_0.40
Lean mass*50.37.6544.416.250.43-0.07_0.92
Fat mass*16.59.1821.59.75-0.52-1.01_-0.02
berg, 2015 (16) (male)Plasma glucose91.817.8393.610.82-0.11-0.31_0.08Age
TC*201.0838.33216.5546.52-0.38-0.58_-0.18
LDL*119.6933.28131.2750.07-0.3-0.5_-0.1
HDL*61.78057.9223.240.320.12_0.52
TG*88.57307.09106.2853.29-0.07-0.26_0.13
SBP*12919.8113418.04-0.26-0.45_-0.06
DBP*809.9859.02-0.52-0.71_-0.32
BMI*22.82.4724.12.7-0.51-0.71_-0.32
Lean mass57.55.9457.45.410.02-0.18_0.21
Fat mass*152.9720.64.51-1.62-1.84_-1.4
Waist*84.47.9289.87.51-0.69-0.89_-0.49
Hip*96.15.4498.95.71-0.51-0.7_-0.31
Berg, 2015 (16) (female)Plasma glucose88.212.1788.210.340-0.19_0.19
TC*204.9752.28216.5533.34-0.23-0.42_-0.04
LDL*111.9752.21119.6933.29-0.16-0.34_0.03
HDL69.526.169.522.190-0.19_0.19
TG*88.5759.9297.4250.91-0.15-0.34_0.04
SBP12513.5212517.240-0.19_0.19
DBP8013.52808.620-0.19_0.19
BMI*22.12.724.12.87-0.73-0.93_-0.54
Lean mass42.84.0542.94.02-0.02-0.21_0.16
Fat mass*17.64.0523.34.88-1.36-1.56_-1.16
WC*60.68.11667.76-0.67-0.86_-0.48
Hip*94.87.4498.96.61-0.56-0.75_-0.37
A. García, 2020 (20) (male)Plasma glucose83.3614.9581.9117.040.09-0.04_0.22Age, BMI and pubertal stage
HDL49.612.9945.7211.750.310.18_0.44
TG*76.7230.885.3238.13-0.25-0.38_-0.12
SBP111.4414.98111.4613.340-0.13_0.13
WC*61.785.1265.856.13-0.73-0.86_-0.59
A. García, 2020 (20) (female)Plasma glucose81.9615.1680.4716.860.09-0.03_0.22
HDL49.6312.5147.1512.210.20.08_0.32
TG*87.1636.6197.8662.59-0.21-0.34_-0.09
SBP107.8112.31110.5812.36-0.22-0.35_-0.1
WC*59.125.0763.945.89-0.88-1.01_-0.75
A. García, 2020 (20)BMI*17.861.8519.671.91-0.96-1.06_-0.87
Fat mass*7.243.099.893.56-0.8-0.89_-0.71
Sohee kim, 2015 (26)Plasma glucose *95.717.599.115.9-0.2-0.32_-0.07Age, sex, and smoking status
TC*192.534.6199.635.5-0.2-0.33_-0.08
LDL*117.130.6123.932.2-0.22-0.35_-0.1
HDL*5112.849.611.30.11-0.01_0.24
TG*106.465.1116.663.3-0.16-0.28_-0.03
SBP*122.515.5128.615.7-0.39-0.52_-0.27
DBP*76.610.179.69.3-0.3-0.43_-0.17
BMI*22.534.323.90.8-0.34-0.47_-0.22
Tayefi, 2019 (28)Plasma glucose86.3835.6691.340.4-0.13-0.21_-0.05Age and sex
TC181.9338.16189.6139.14-0.2-0.28_-0.12
LDL113.1933.54117.6735.06-0.13-0.21_-0.05
HDL*42.099.845.749.43-0.38-0.46_-0.3
TG*105738.93126753.96-0.03-0.11_0.05
SBP*116.2616.39118.119.9-0.1-0.18_-0.02
DBP*76.3511.8475.7511.850.05-0.03_0.13
BMI*22.623.3823.394.18-0.2-0.28_-0.12
WC*84.529.8986.0111.53-0.14-0.22_-0.06
Hip*94.226.9196.888.86-0.34-0.42_-0.26
A. Romero, 2010 (6) (male)Plasma glucose95.615.9296.822.32-0.06-0.15_0.03Age and race
HOMA*0.840.3110.63-0.32-0.41_-0.23
LDL*121.849.03132.6449.11-0.22-0.31_-0.13
HDL*49.1112.147.5612.110.130.04_0.22
TG*116.0384.38113.7584.510.03-0.06_0.11
SBP12215.9212515.94-0.19-0.28_-0.1
DBP7412.73769.57-0.18-0.26_-0.09
BMI*22.71.2723.51.27-0.63-0.72_-0.54
WC*84.86.0588.96.37-0.66-0.75_-0.57
Lean mass*55.45.73535.740.420.33_0.51
Fat mass*14.61.5918.52.55-1.83-1.94_-1.73
Hip*93.24.1394.64.14-0.34-0.43_-0.25
A. Romero, W2010 (6) (female)Plasma glucose9222.5791.122.620.04-0.05_0.13
HOMA*0.870.320.980.64-0.22-0.3_-0.13
LDL*116.449.66124.1362.39-0.14-0.22_-0.05
HDL5812.2557.6212.280.03-0.05_0.12
TG*100.9785.46136.4228.87-0.2-0.29_-0.12
SBP11719.3411920.04-0.1-0.19_-0.02
DBP719.6772.110.34-0.11-0.2_-0.02
BMI*22.11.2923.50.97-1.23-1.32_-1.13
WC*78.36.4583.36.46-0.77-0.86_-0.69
Lean mass*40.214.1939.93.550.08-0.01_0.17
Fat mass*18.11.9322.12.26-1.9-2.01_-1.8
Hip*94.44.5197.74.85-0.7-0.79_-0.62
K. E. Martinez, 2017 (31)HOMA*1.12.011.61.52-0.26-0.38_-0.13Age, sex, race, and year of assessment. moderate physical activity, vigorous physical activity, and smoking
P. Marques-Vidal, 2010 (32)Plasma insulin8.5613.888.176.970.03-0.13_0.19Age
HOMA3.325.713.182.890.03-0.13_0.18
BMI*21.84.08232.63-0.3-0.46_-0.15
WC*75.98.1679.97.89-0.49-0.65_-0.33
Hip*94.48.1696.16.57-0.21-0.37_-0.06

Association of NWO with mean of CMRFs in included studies.

CMRFs, cardio-metabolic risk factors; NWNO, normal weight non obese; NWO, Normal weight obesity; M, male; F, female; TC, total cholesterol; HOMA, Homeostatic Model Assessment for Insulin Resistance; LDL, low-density lipoproteins; HDL, high-density lipoproteins; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; SMD, Standardized Mean Difference; SD, Standard Deviation; CI, Confidence Interval. Plasma glucose, TC, LDL, HDL, TG values are reported in the mg/dL unit. SBP and DBP in mmHg, BMI In kilograms by height (in meters) squared, lean and fat masses in kilograms, Hip and WC in centimeters.

*Statistically significant (p-value < 0.05).

The SMDs were calculated based on Hedges’ g formula.

Table 3

Author YearOutcomeDefinition of outcomeOR (95% CI)**Adjustment
W. K. Cho 2015 (17) (Male)HOMAFasting glucose (in millimoles per liter) × fasting insulin (in milliunits per liter)/22.52.46 (1.21-4.99)Age, weight, and ALT
W. K. Cho 2015 (17) (Female)HOMA1.51 (0.83-2.75)
M. Correa 2020 (18)hyperglycemiaFBS ≥5.6 mmol/L [100 mg/dL]1.31 (0.73-2.33)Age and sex
HTN≥130 mm Hg SBP and/ or DBP 85 mm Hg1.42 (0.89-2.27)
Elevated TG≥1.7 mmol/L [151 mg/dL]1.31 (0.62-2.76)
Elevated LDL≥2.6 mmol/L [100 mg/dL]1.27 (0.85-1.90)
Reduced HDLlow HDL: < 1 mmol/L [38.7 mg/dL] in men and 1.3 mmol/L [50.3 mg/dL] in women2.34 (1.61-3.93)*
Cardiometabolic risk Z-score+ 1 SD above the mean3.10 (2.06-4.67)*
obesityWaist to hip ratio > 0.49 in men and > 0.50 in women2.61 (0.69-9.87)
Abdominal ObesityWC ≥ 90 cm in men, and ≥ 80 cm in women7.27 (1.09-48.60)*
Ramsaran 2017 (19)Elevate DBPhigh SBP and DBP systolic  ≥ 120 mm Hg and the diastolic  ≥ 80 mm Hg0.98 (0.39-2.48)Not adjusted
Elevate SBP1.85 (0.52-5.52)
Elevated WCmen  ≥ 94 cm and women  ≥ 80 cm26.61 (4.75-149.14)*
H. He 2019 (21)HTNSBP ≥  140 and,or DBP  ≥ 901.82 (1.43-2.30)*Age, sex, social economic profiles, lifestyle factors, family history of HTN and other disease status, etc.
A. Jia 2018 (22)DMFBS 7.0  ≥ mmol/L; blood glucose 2 h after an OGTT  ≥ 11.1 mmol/L; a previous diagnosis of diabetes; or current use of hypoglycemic agents1.44 (1.10–1.88)*Age , sex, ethnicity, smoking, alcohol use, exercise, education, yearly family income, family history of disease, and WC
HTNSBP ≥  130 and,or DBP  ≥851.53 (1.27–1.84)*
MetSIDF11.48 (1.22–1.79)*
Elevated Framingham riskScore ≥ 10%2.36 (1.76–3.17)*
Kapoor 2020 (23)DMFBS ≥ 126 mg/dl and/or 2-h plasma glucose value of ≥ 200 mg/dl were diagnosed to have diabetes/2.72 (1.46–5.08)*Age, sex, tobacco use and alcohol intake
HTNSBP ≥  140 and, or DBP  ≥ 901.89 (0.92–3.86)
Dyslipidemiataking lipid-lowering medications and/or TC >200 mg/dl and/or LDL >100 mg/dl and/or HDL <40 mg/dl in men and <50 mg/dl in women and/ or TG >200 mg/dl.2.37 (1.55–3.64)*
Kim, 2014 (24) (Male)DMfasting blood glucose ≥ 126 mg/dl or treatment of the disease1.38 (1.04 -1.83)*Age and lifestyle factors
HTNSBP ≥  140 and, or DBP  ≥ 901.70 (1.42 - 2.02)*
dyslipidemiatotal cholesterol  ≥ 240 mg/dl and/or high-density lipoprotein (HDL) cholesterol <40 mg/dl and/or triglyceride  ≥ 150 mg/dl or treatment of dyslipidemia**2.69 (2.29 - 3.17)*
MetS2.50 ( 2.10 - 2.97)*
Mets risk factor above 1plus 1 metabolic risk odds3.54 ( 2.89 - 4.34)*
Kim, 2014 (24) (Female)DMfasting blood glucose ≥ 126 mg/dl or treatment of the disease1.72 (1.30 - 2.29)*
HTNSBP ≥  130 mmHg and, or DBP  ≥85 mmHg1.52 (1.25 - 1.86)*
dyslipidemiatotal cholesterol  ≥ 240 mg/dl and/or high-density lipoprotein (HDL) cholesterol <40 mg/dl and/or triglyceride  ≥ 150 mg/dl or treatment of dyslipidemia**1.70 (1.40 - 2.06)*
MetS1.80 (1.48 - 2.20)*
Mets risk factor above 1plus 1 metabolik risk odds2.47 (2.01 - 3.03)*
Kim 2018 (25)MetSIDF1.83 (1.21 - 2.76)*Potential confounders
Plaque formation risk (–)1.46 (1.027 - 2.07)*
H. Zhao 2012 (27)HTN risk (-)2.18*Age and sex
Hyperglycemia2.12*
dyslipidemia2.08*
Hyperuricemia3.49*
Tayefi 2019 (28)Risk of metabolically abnormal phenotype (-)2.02 (1.68-2.42)*Age and sex
Cardiac risk (Q)QRISK calculated online by using the Framingham risk equation6 (4.45-8.08)*
T. Shirasawa 2019 (8) (Male)DMFBS ≥ 126 mg/dl, random plasma glucose ≥ 200 mg/dl, HbA1c (National Glycohemoglobin Standardization Program) ≥ 6.5%, or receiving medical treatment for DM1.35 (1.25-1.46)*Age, weight, smoking status, alcohol intake, and physical activity
HTNSBP ≥  140 and, or DBP  ≥ 90 or taking medication for HTN1.22 (1.17-1.27)*
Dyslipidemiaas LDL-C ≥ 140 mg/dl, HDL-C < 40 mg/dl, TG ≥ 150 mg/dl, or taking medication for dyslipidemia1.84 (1.74-1.89)*
T. Shirasawa 2019 (8) (Female)DMFBS ≥ 126 mg/dl, random plasma glucose ≥ 200 mg/dl, HbA1c ≥ 6.5%, or receiving medical treatment for DM1.60 (1.35-1.90)*
HTNSBP ≥  140 and,or DBP  ≥ 90 or taking medication for hypertension1.23 (1.16-1.31)*
dyslipidemiaas LDL-C ≥ 140 mg/dl, HDL-C < 40 mg/dl, triglycerides ≥ 150 mg/dl, or taking medication for dyslipidemia1.60 (1.52-1.69)*
A. S. Olafsdottir (29)MetsIDF2.2 (1.2-3.9)not adjusted
F. M. Moy 2015 (30)Elevated TGTG ≥ 1.7 mmol/L2.51 (1.47–4.29)*age and ethnicity
Reduced HDLHDL-C ≤ 1.3 mmol/L in women1.09 (0.75–1.58)
Hypertensionsystolic ≥130 mmHg and/or diastolic ≥85 mmHg or on antihypertensive treatment1.63 (1.15–2.31)*
HyperglycemiaFBG ≥ 5.6 mmol/L1.67 (0.90–3.08
MetsIDF1.70 (0.87–3.32)
Hypercholesterolemia (–)2.22 (0.21–23.20)
DiabetesHyperglycemia: FBG ≥ 5.6 mmol/L.1.28 (0.34–4.92)
P. Marques-Vidal 2010 (32)Elevated TGTG ≥ 1.7 mmol/L [151 mg/dL] and/or LDL  ≥ 2.6 mmol/L [100 mg/dL] (in the presence of myocardial infarction, stroke, coronary artery disease or diabetes) and  ≥ 4.2 mmol/L [163 mg/dL] in other cases and/or hypolipidaemic drug treatment2.21 (1.43-3.42)*
Low HDL1 mmol/L in men and 1.3 mmol/L in women2.10 (1.23-3.57)*
HTN (–)1.38 (0.97-1.98)*
Hyperglycemiafasting hyperglycemia; HOMA > 4.88 (90th percentile in men) or >3.57 (90th percentile in women)1.63 (1.10-2.42)*
dyslipidemiaHDL < 1 mmol/L in men and 1.3 mmol/L in women and/or TG  ≥ 1.7 mmol/L [151 mg/dL] and/or LDL  ≥ 2.6 mmol/L [100 mg/dL] (in the presence of myocardial infarction, stroke, coronary artery disease or diabetes) and ≥ 4.2 mmol/L [163 mg/dL] in other cases and/or hypolipidaemic drug treatment1.90 (1.34-2.68)*
CMRFthe presence of at least two of the following: HTN ; TG  ≥ 1.7 mmol/L; HDL cholesterol < 1 mmol/L [38.7 mg/dL] in men and 1.3 mmol/L [50.3 mg/dL] in women; fasting hyperglycemia; HOMA > 4.88 (90th percentile in men) or >3.57 (90th percentile in women) and CRP > 5.2 mg/L (90th percentile in men) or >6.1 mg/L (90th percentile in women) , definition 1. A second definition of metabolic risk was also applied, using the same criteria but with HOMA > 5.0 and CRP > 4.0 mg/L1.37 (0.97-1.95)*
Abdominal obesity (–)2.64 (1.73–4.04)*
F. B. Madeira 2013 (4)Elevated TGTG ≥ 150 mg/dL, use of lipid medications or self-reported diagnosis of hypertriglyceridemia1.89 (0.97-3.70)age, sex, skin colour, early and adult life variables (alcohol consumption, family income, schooling, marital status, smoking, percentage of fat in the diet and physical activity
Reduced HDLHDL < 40 mg/dL for men and ,50 mg/dL for women1.53 (1.00-2.34)
HTNSBP ≥ 130 mmHg and/ DBP ≥ 85 mmHg, current usage of antihypertensive drugs or previous diagnosis of hypertension1.17 (0.65-2.13)
Hyperglycemiahigh fasting blood glucose (≥100 mg/dL), current use of anti-diabetic medication or previously diagnosed diabetes2.68 (1.01-7.12)*
HOMA (–)4.91 (1.85-13.04)*
MetsIDF8.89 (3.32-4.47)*
Elevated WCcentral obesity (WC ≥ 90 cm for men and ≥ 80 cm for women9.27 (5.32-16.15)*
P. J. Liu 2017 (33)Elevated TGTGs ≥1.7 mmol/L2.13 (1.10-4.12)*age, smoking status ,drinking status, total cholesterol, LDL-c, high sensitivity C-reactive protein, and the remaining non-adipose MetS components, body fat percentage
Reduced HDLHDL <1.30 mmol1.04 (0.61-1.75)
HTNblood pressure ≥130/85 mmHg or current antihypertensive medication use2.06 (1.09-3.90)*
HyperglycemiaFBS ≥5.6 mmol/L, type 2 diabetes mellitus previously diagnosed by a physician, or current antidiabetic medication use1.44 (0.77-2.68)
Mets risk factor above 2IDF2.00 (1.19-3.33)*
C. C. N. Da Silva 2021 (34)Elevated TGTG levels above 150 mg/dL or use of lipid-lowering drugs1.77 (1.12-2.79)*total calories, family income, added sugar intake, total lipids intake, and physical activity
Reduced HDL<40 mg/dL for men and <50 mg/dL for women or use of lipid-lowering drugs1.27 (0.98-1.65)
HTNSBP > 130 mmHg, DBP > 85 mmHg, or use of antihypertensive drugs1.44 (0.94-2.21)
HyperglycemiaFBS  > 100 mg/dL or use of glucose-lowering drugs1.48 (0.96-1.65)
MetsIDF1.87 (1.36-2.57)*
Elevated WCWC 90 cm for men and 80 cm for women9.27 (5.32-16.15)*

Association of NWO with CMRFs in included studies.

NWO, Normal weight obesity, M, male, F, female, TC, total cholesterol, HOMA, Homeostatic Model Assessment for Insulin Resistance, LDL, low-density lipoproteins, HDL, high-density lipoproteins, TG, triglyceride, SBP, systolic blood pressure, DBP, diastolic blood pressure, BMI, body mass index, WC, waist circumference, Mets, metabolic syndrome, DM, diabetes mellitus, HTN, hypertension, CM, centimeters, IDF, International Diabetes Federation, OR, odds ratio, CI, Confidence Interval.

*Statistically significant (p-value < 0.05).

**OR calculated for NWO compare to NWNO.

1MetS is defined based on the criteria of IDF.

Quantitative Synthesis

The overall and sex-stratified pooled ORs of the relationship between NWO and CMRFs are shown in Table 4. The result of the meta-analysis showed that the overall odds ratio of hyperglycemia increased by 50% (OR:1.50, 95%:1.23, 1.76), of high TG by 90% (OR:1.90, 95% CH:1.44, 2.35), of low HDL by 28% (OR: 1.28, 95% CI:1.06, 1.49) and of diabetes by 39% (OR:1.39, 95% CI:1.30, 1.49) among NWO individuals. Also, the random effect meta-analysis showed increased odds of dyslipidemia by 83% (OR:1.83, 95% CI:1.61, 20.4), of HTN by 40% (OR:1.40, 95% CI:1.28, 1.51) and of metabolic syndrome by 92% (OR:1.92, 95% CI:1.58, 2.26) in the same population (Figure 2).

Table 4

variablesNo studySample sizePooled odds ratio (95% CI)Heterogeneity assessment
I-squared %ModelP-value
Hyperglycemia
Overall66,9341.50 (1.23, 1.76)*0.00Fixed0.958
Both sexes33,3631.46 (1.15, 1.78)0.00Fixed0.684
Female33,5711.58 (1.10, 2.07)*0.00Fixed0.937
HTN
Overall13155,3971.40 (1.28, 1.51)*57.30Random0.005
Both sexes521,6591.56 (1.35, 1.78)*0.00Fixed0.587
Male287,8001.43 (0.96, 1.90)89.50Random0.002
Female645,9381.25 (1.18, 1.33)*25.80Fixed0.241
High TG
Overall66,9341.90 (1.44, 2.35)*0.00Fixed0.785
Both sexes33,3631.65 (1.05, 2.24)*0.00Fixed0.746
Female33,5712.26 (1.55, 2.98)*0.00Fixed0.924
Low HDL
Overall66,9341.28 (1.06, 1.49)*29.80Fixed0.212
Both sexes33,3631.38 (1.09, 1.67)*38.20Fixed0.198
Female33,5711.15 (0.82, 1.47)27.40Fixed0.252
Diabetes
Overall7146,6761.39 (1.30, 1.49)*9.30Fixed0.358
Both sexes216,4381.49 (1.11, 1.87)*45.5Fixed0.175
Male287,8001.35 (1.25, 1.45)*0.00Fixed0.886
Female342,4381.62 (1.38, 1.86)*0.00Fixed0.878
Metabolic syndrome
Overall636,8541.92 (1.58, 2.26)*68.40Random0.002
Both sexes523,6881.82 (1.38, 2.26)*66.40Random0.018
Female27,7621.79 (1.44, 2.13)*0.00Fixed0.878
Dyslipidemia
Overall7135,2761.83 (1.61, 2.04)*80.00Random<0.001
Both sexes32,7371.73 (0.86, 2.60)*45.70Random0.159
Male287,8002.23 (1.40, 3.06)*92.80Random<0.001
Female444,7391.61 (1.52, 1.69)*80.00Random<0.001

Stratified meta-analysis of association between NWO with CMRFs according to sex.

*Statistically significant (P-value < 0.05)

HDL, high-density lipoproteins; TG, triglyceride; HTN, hypertension; No, number; CI, confidence interval; CMRFs, cardio-metabolic risk factors; NWO, Normal weight obesity; HDL, high-density lipoproteins; TG, triglyceride; HTN, hypertension; No, number; CI, confidence interval; CMRFs, cardio-metabolic risk factors; NWO, Normal weight obesity.

Figure 2

Figure 2

Forest plot detailing the pooled association between NWO with CMRFs.

The overall and sex-stratified association between NWO and the mean of CMRFs are shown in Table 5. A low to high heterogeneity was seen among included studies based on the CMRFs. Based on the fixed-effect model meta-analysis, the overall mean of TC (SMD: 0.22, 95% CI: 0.16, 0.28) and LDL (SMD: 17, 95% CI: 0.13, 0.12) was higher in NWO individuals compared to the normal weight none obese (NWNO) individuals. Based on the random effect meta-analysis, being NWO statistically increased the mean of HOMA (SMD: 0.12, 95% CI: 0.09, 0.32), TG (SMD: 0.13, 95% CI: 0.05, 0.20), SBP (SMD: 0.15, 95% CI: 0.07, 0.23), DBP (SMD: 0.16, 95% CI: 0.03, 0.29). However, the relationship between plasma glucose, HDL and lean mass was not statistically significant (Figure 3).

Table 5

Variables No studySample sizeSMD (95% CI)Heterogeneity assessment
I-squared %ModelP-value
Plasma glucose
Overall912,3120.03 (-0.04, 0.10)66.30Random0.003
Both sexes34,8060.14 (0.07, 0.21)*0.00Fixed0.410
Male33,5100.02 (-0.04, 0.09)54.90Fixed0.109
Female33,996-0.05 (-0.11, 0.01)0.00Random0.672
Total cholesterol
Overall56,2770.22 (0.16, 0.28)*0.00Fixed0.559
Both sexes33,1320.20 (0.13, 0.26)*0.00Fixed0.976
HOMA
Overall510,3060.21 (0.09, 0.32)*73.10Random0.005
Both sexes23,8890.26 (0.14, 0.38)*0.00Fixed0.765
Female24,3900.10 (-0.13, 0.34)85.9Random0.008
LDL
Overall710,3930.17 (0.13, 0.21)*0.00Fixed0.503
Both34,8060.15 (0.09, 0.22)*0.00Fixed0.437
Male22,6080.23 (0.15, 0.34)*0.00Fixed0.465
Female22,9790.14 (0.06, 0.21)*0.00Fixed0.865
HDL
Overall812,312-0.08 (-0.26, 0.10)94.70Random<0.001
Both sexes34,806-0.01 (-0.44, 0.41)95.90Random<0.001
Male23,510-0.21 (-0.39, -0.03)80.70Random0.023
Female33,996-0.08 (-0.20, 0.04)94.70Random<0.001
TG
Overall912,3120.13 (0.05, 0.20)*70.30Random0.001
Both sexes34,8060.09 (-0.02, 0.21)50.30Fixed0.133
Male33,5100.05 (-0.09, 0.12)83.20Random0.003
Female33,9960.20 (0.13, 0.26)*0.00Fixed0.858
SBP
Overall612,3120.15 (0.07, 0.23)*71.80Random<0.001
Both sexes34,8060.19 (-0.06, 0.44)87.20Random<0.001
Male33,5100.14 (0.01, 0.28)*70.80Random0.033
Female33,9960.12 (0.05, 0.19)*55.20Fixed0.107
DBP
Overall510,3930.16 (0.03, 0.29)*86.50Random<0.001
Both sexes34,8060.10 (-0.18, 0.40)90.60Random<0.001
Male22,6080.33 (0.004, 0.66)*89.50Random0.002
Female22,9790.09 (0.01, 0.17)*7.10Fixed0.300
Lean mass
Overall55,876-0.16 (-0.37, 0.04)90.20Random<0.001
Male22,608-0.22 (-0.62, 0.16)92.60Random<0.001
Female22,979-0.06 (-0.14, 0.01)0.00Fixed0.323
Fat mass
Overall67,7951.36 (0.89, 1.82)*98.50Random<0.001
Both sexes22,2080.79 (0.69, 0.88)*12.00Fixed0.284
Male22,6081.75 (1.54, 1.95)*66.30Random0.085
Female22,9791.63 (1.10, 2.17)*95.50Random<0.001
Waist circumference
Overall812,2460.62 (0.42, 0.83)*95.80Random<0.001
Male3N.R0.68 (0.61, 0.75)0.716Fixed0.716
Female4N.R0.71 (0.56, 86.50)80.30Random0.002
Hip circumference
Overall512,2460.44 (0.28, 0.60)*91.00Random<0.001
Male23,5100.36 (0.24, 0.55)57.80Fixed0.124
Female26,2970.49 (0.18, 0.80)93.10Random<0.001

Stratified meta-analysis of association between NWO with mean of CMRFs according to sex.

*Statistically significant (P-value < 0.05).

HOMA, Homeostatic Model Assessment for Insulin Resistance; LDL, low-density lipoproteins; HDL, high-density lipoproteins; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension; No, number; CI, confidence interval; CMRFs, cardio-metabolic risk factors; NWO, Normal weight obesity; HDL, high-density lipoproteins; TG, triglyceride; HTN, hypertension; No, number; CI, confidence interval; CMRFs, cardio-metabolic risk factors; NWO, Normal weight obesity; SMD, Standardized Mean Difference; N.R, Not Reported.

Figure 3

Figure 3

Forest plot detailing the pooled association between NWO with mean CMRFs.

Publication Bias

Except for HTN (coefficient =1.70, p-value=0.003), no publication bias was observed in articles studying the association between NWO and CMRFs for dichotomous and continuous data.

Sensitivity Analysis

The sensitivity analysis result indicated that the pooled OR of the relationship between NWO and HTN was not substantially affected by each study (OR:1.23, 95% CI:1.19, 1.27).

Discussion

To our knowledge, this is the first systematic review and meta-analysis that compared CMRFs among NWO and NWNO individuals across the entire population. We found 50% and 42% increased odds of hyperglycemia and diabetes among NWO individuals compared to the NWNOs, respectively. NWO individuals also have 40%, 83%, and 32% increased odds of HTN, dyslipidemia, and reduced HDL levels, respectively. Interestingly, NWO individuals also had an increased odds of hypertriglyceridemia as high as 90%. The results of other studies, such as Yu et al. (37) on CMRFs across various types of obesity, are comparable to that of ours. In the aforementioned study, the odds of hyperglycemia and diabetes were 40% and 103% in those with central obesity, 78% odds of HTN, and 142% hypertriglyceridemia (37). Although it seems that NWO imposes less a CMRF, some of its complications are comparable to that of obesity (central, general, and combined) (34); furthermore, despite being in a relatively better status than the obese, NWO individuals have a significantly greater CMRFs in comparison to the NWNOs. Moreover, the assessment of NWO-related comorbidities is of particular importance since the prevalence of NWO is exceptionally high (ranging from 5 to 45% based on sex, age, and the definition of NWO) (29, 38, 39). With a prevalence of 45% even among adolescents, NWO acts as a potent risk factor for future comorbidities; Hence, preventing and treating NWO can drastically reduce these comorbidities as well as obesity in adulthood; nonetheless, seemingly, due to lifestyle changes, unhealthy diets and lack of adequate physical activity, and sedentary lifestyle, the prevalence of NWO is increasing in a worrisome manner (40). However, these NWO individuals will go unnoticed and undiagnosed due to the inadequacies of BMI measurement, and despite their high body fat, due to their normal BMI levels, no treatment and preventive measure will be taken until it is too late. Furthermore, although obesity is a well-known associate of metabolic dysregulation, and there have been numerous studies on conditions that can result from obesity, yet the new concept of obesity (in which the weight itself is not as important as the body’s fat percent) is not well known nor studied. There have been studies on normal weight obesity regarding the conditions that can arise from it; however, compared to obesity, the number of studies are preliminary and more studies need to be done so that normal weight obesity gets the recognition that it needs as it is imperative for individuals to be well aware of their condition in order to take preventive measures. The public must be educated on the subject of NWO and must know that a normal BMI does not necessarily mean that they are not obese; in fact, they might have normal weight obesity, and regardless of their normal BMI, they are at increased risk of cardiometabolic conditions.

Limitations and Strength

To the best of our knowledge, this is the first systematic review and meta-analysis comparing CMRFs among NWO and NWNO individuals in the entire population (age range 13 to 75), with a sample size of 177,792 proper research methods, it gives a realistic status of NWO globally. Our limitations were the use of manuscripts with an English full text. Furthermore, the unequal number of studies in different countries and differences in measurement and methodological aspects of the included studies resulting in high heterogeneity were among our limitations.

Conclusion

The present study illustrated the significant odds of CMRFs among NWO individuals compared to subjects with NWNO. Indicating the inadequacy of the BMI measurement and the need for body fat assessment instead, for a better risk assessment. Furthermore, the necessity of preventive measures and interventions to significantly reduce the burden of the aforementioned condition is essential to avoid the upcoming obesity pandemic.

Funding

This study was funded by Alborz University of Medical Sciences.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

NK, MQ, and OT-M designed the study. NK and SN searched the databases. NK and SN screened and extracted the data. ES screened and analyzed the data. MQ, NK, OTM, RK, and MHB prepared the results. NK, MQ, and ZA wrote the paper. All other authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.857930/full#supplementary-material

Abbreviations

NWO, Normal weight obesity; CMRFs, cardio-metabolic risk factors; NWNO, normal weight non obese; M, male; F, female; TC, total cholesterol; HOMA, Homeostatic Model Assessment for Insulin Resistance; LDL, low-density lipoproteins; HDL, high-density lipoproteins; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; MetS, metabolic syndrome; DM, diabetes mellitus; HTN, hypertension; CM, centimeters; IDF, International Diabetes Federation; SMD, Standardized Mean Difference; OR, odds ratio; SD, Standard Deviation; CI, Confidence Interval; Q.A, quality assessment.

References

  • 1

    KellyTYangWChenC-SReynoldsKHeJ. Global Burden of Obesity in 2005 and Projections to 2030. Int J Obes (2008) 32(9):1431–7. doi: 10.1038/ijo.2008.102

  • 2

    ApovianCM. Obesity: Definition, Comorbidities, Causes, and Burden. Am J Manag Care (2016) 22(7 Suppl):s176–85.

  • 3

    TremmelMGerdthamU-GNilssonPMSahaS. Economic Burden of Obesity: A Systematic Literature Review. Int J Environ Res Public Health (2017) 14(4):435. doi: 10.3390/ijerph14040435

  • 4

    MadeiraFBSilvaAAVelosoHFGoldaniMZKacGCardosoVCet al. Normal Weight Obesity Is Associated With Metabolic Syndrome and Insulin Resistance in Young Adults From a Middle-Income Country. PloS One (2013) 8(3):e60673. doi: 10.1371/journal.pone.0060673

  • 5

    JeanNSomersVKSochorOMedina-InojosaJLlanoEMLopez-JimenezF. Normal-Weight Obesity: Implications for Cardiovascular Health. Curr Atheroscl Rep (2014) 16(12):18. doi: 10.1007/s11883-014-0464-7

  • 6

    Romero-CorralASomersVKSierra-JohnsonJKorenfeldYBoarinSKorinekJet al. Normal Weight Obesity: A Risk Factor for Cardiometabolic Dysregulation and Cardiovascular Mortality. Eur Heart J (2010) 31(6):737–46. doi: 10.1093/eurheartj/ehp487

  • 7

    RothmanKJ. BMI-Related Errors in the Measurement of Obesity. Int J Obes (2008) 32(3):S56–S9. doi: 10.1038/ijo.2008.87

  • 8

    ShirasawaTOchiaiHYoshimotoTNagahamaSKobayashiMOhtsuIet al. Associations Between Normal Weight Central Obesity and Cardiovascular Disease Risk Factors in Japanese Middle-Aged Adults: A Cross-Sectional Study. J Health Population Nutr (2019) 38(1):17. doi: 10.1186/s41043-019-0201-5

  • 9

    SuligaEKoziełDGłuszekS. Prevalence of Metabolic Syndrome in Normal Weight Individuals. Ann Agric Environ Med (2016) 23(4):631–5. doi: 10.5604/12321966.1226858

  • 10

    OliverosESomersVKSochorOGoelKLopez-JimenezF. The Concept of Normal Weight Obesity. Prog Cardiovasc Dis (2014) 56(4):426–33. doi: 10.1016/j.pcad.2013.10.003

  • 11

    FinkelsteinEAKhavjouOAThompsonHTrogdonJGPanLSherryBet al. Obesity and Severe Obesity Forecasts Through 2030. Am J Prev Med (2012) 42(6):563–70. doi: 10.1016/j.amepre.2011.10.026

  • 12

    LuharSTimæusIMJonesRCunninghamSPatelSAKinraSet al. Forecasting the Prevalence of Overweight and Obesity in India to 2040. PloS One (2020) 15(2):e0229438. doi: 10.1371/journal.pone.0229438

  • 13

    RobinsonE. Overweight But Unseen: A Review of the Underestimation of Weight Status and a Visual Normalization Theory. Obes Rev (2017) 18(10):1200–9. doi: 10.1111/obr.12570

  • 14

    HigginsJPThompsonSGDeeksJJAltmanDG. Measuring Inconsistency in Meta-Analyses. Bmj (2003) 327(7414):557–60. doi: 10.1136/bmj.327.7414.557

  • 15

    BellissimoMPCaiQZieglerTRLiuKHTranPHVosMBet al. Plasma High-Resolution Metabolomics Differentiates Adults With Normal Weight Obesity From Lean Individuals. Obesity (2019) 27(11):1729–37. doi: 10.1002/oby.22654

  • 16

    BergCStrandhagenEMehligKSubramoneySLissnerLBjörckL. Normal Weight Adiposity in a Swedish Population: How Well is Cardiovascular Risk Associated With Excess Body Fat Captured by BMI? Obes Sci Pract (2015) 1:50–8. doi: 10.1002/osp4.4

  • 17

    ChoWKKimHLeeHYHanKDJeonYJJungIAet al. Insulin Resistance of Normal Weight Central Obese Adolescents in Korea Stratified by Waist to Height Ratio: Results From the Korea National Health and Nutrition Examination Surveys 2008–2010. Int J Endocrinol (2015) 2015:158758. doi: 10.1155/2015/158758

  • 18

    Correa-RodríguezMGonzález-RuízKRincón-PabónDIzquierdoMGarcía-HermosoAAgostinis-SobrinhoCet al. Normal-Weight Obesity Is Associated With Increased Cardiometabolic Risk in Young Adults. Nutrients (2020) 12(4):1106. doi: 10.3390/nu12041106

  • 19

    RamsaranCMaharajRG. Normal Weight Obesity Among Young Adults in Trinidad and Tobago: Prevalence and Associated Factors. Int J Adolesc Med Health (2017) 29. doi: 10.1515/ijamh-2015-0042

  • 20

    García-HermosoAAgostinis-SobrinhoCCamargo-VillalbaGEGonzález-JiménezNMIzquierdoMCorrea-BautistaJE. Normal-Weight Obesity Is Associated With Poorer Cardiometabolic Profile and Lower Physical Fitness Levels in Children and Adolescents. Nutrients (2020) 12:1171. doi: 10.3390/nu12041171

  • 21

    HeHPanLLiuFMaJHuZWangL. Expanded Normal Weight Obesity and Blood Pressure in Chinese Adults: A Community-Based Crosss-Ectional Study. Austral J Prim Health (2019) 25. doi: 10.1071/PY18166

  • 22

    JiaAXuSXingYZhangWYuXZhaoY. Prevalence and Cardiometabolic Risks of Normal Weight Obesity in Chinese Population: A Nationwide Study. Nutr Metab Cardiovasc Dis (2018) 28:1045–53. doi: 10.1016/j.numecd.2018.06.015

  • 23

    KapoorNLotfalianyMSathishTThankappanKRThomasNFurlerJet al. Prevalence of Normal Weight Obesity and its Associated Cardio-Metabolic Risk Factors–Results From the Baseline Data of the Kerala Diabetes Prevention Program (KDPP). PloS One (2020) 15(8):e0237974. doi: 10.1371/journal.pone.0237974

  • 24

    KimMKHanKKwonHSSongKHYimHWLeeWCet al. Normal Weight Obesity in K Orean Adults. Clin Endocrinol (2014) 80(2):214–20. doi: 10.1111/cen.12162

  • 25

    KimSJooHJShimW-JLeeJ. Normal Weight Obesity and Metabolic Syndrome Risk in Korean Adults: 5-Year Longitudinal Health Checkup Study. Circulation (2018) 138(Suppl_1):A13448–A.

  • 26

    KimSKyungCParkJSLeeS-PKimHKAhnCWet al. Normal-Weight Obesity is Associated With Increased Risk of Subclinical Atherosclerosis. Cardiovasc Diabetol (2015) 14(1):19. doi: 10.1186/s12933-015-0220-5

  • 27

    ZhaoHLengSLiuYSunGShujunY. Relationship Between Normal Weight Obesity and Cardiovascular Risk Factors. Chin J Health Manage (2012) 6(4):255–8. doi: 10.3760/cma.j.issn.1674-0815.2012.04.011

  • 28

    TayefiMTayefiBDarroudiSMohammadi-BajgiranMMouhebatiMHeidari-BakavoliAet al. There Is an Association Between Body Fat Percentage and Metabolic Abnormality in Normal Weight Subjects: Iranian Large Population. Trans Metab Syndrome Res (2019) 2(1):11–6. doi: 10.1016/j.tmsr.2019.08.001

  • 29

    OlafsdottirASTorfadottirJEArngrimssonSA. Health Behavior and Metabolic Risk Factors Associated With Normal Weight Obesity in Adolescents. PloS One (2016) 11(8):e0161451. doi: 10.1371/journal.pone.0161451

  • 30

    MoyFMLohDA. Cardiometabolic Risks Profile of Normal Weight Obese and Multi-Ethnic Women in a Developing Country. Maturitas (2015) 81(3):389–93. doi: 10.1016/j.maturitas.2015.04.011

  • 31

    MartinezKETuckerLABaileyBWLeCheminantJD. Expanded Normal Weight Obesity and Insulin Resistance in US Adults of the National Health and Nutrition Examination Survey. Maturitas (2017) 81(3):389–93. doi: 10.1016/j.maturitas.2015.04.011

  • 32

    Marques-VidalPPécoudAHayozDPaccaudFMooserVWaeberGet al. Normal Weight Obesity: Relationship With Lipids, Glycaemic Status, Liver Enzymes and Inflammation. Nutrition Metab Cardiovasc Dis (2010) 20(9):669–75. doi: 10.1016/j.numecd.2009.06.001

  • 33

    LiuPJMaFLouHPZhuYN. Normal-Weight Central Obesity Is Associated With Metabolic Disorders in Chinese Postmenopausal Women. Asia Pac J Clin Nutr (2017) 26(4):692–7. doi: 10.1016/j.numecd.2009.06.001

  • 34

    da Silva CoelhoCCNBragançaMLBMde OliveiraBRBettiolHBarbieriMACardosoVCet al. Incidence of Metabolic Syndrome in Adults With Healthy Weight, Normal Weight Obesity, and Overweight/Obesity. Nutrition (2021) 85:111134. doi: 10.1016/j.nut.2020.111134

  • 35

    XuSMingJJiaAYuXCaiJJingCet al. Normal Weight Obesity and the Risk of Diabetes in Chinese People: A 9-Year Population-Based Cohort Study. Sci Rep (2021) 11(1):18. doi: 10.1038/s41598-021-85573-z

  • 36

    WiklundPTörmäkangasTShiYWuNVainionpääAAlenMet al. Normal-Weight Obesity and Cardiometabolic Risk: A 7-Year Longitudinal Study in Girls From Prepuberty to Early Adulthood. Obesity (2017) 25(6):1077–82. doi: 10.1002/oby.21838

  • 37

    YuSXingLDuZTianYJingLYanHet al. Prevalence of Obesity and Associated Risk Factors and Cardiometabolic Comorbidities in Rural Northeast China. BioMed Res Int (2019) 2019:6509083. doi: 10.1155/2019/6509083

  • 38

    Marques-VidalPChioleroAPaccaudF. Large Differences in the Prevalence of Normal Weight Obesity Using Various Cut-Offs for Excess Body Fat. Eur e-J Clin Nutr Metab (2008) 3:e159–62. doi: 10.1016/j.eclnm.2008.05.003

  • 39

    ConusFRabasa-LhoretRPeronnetF. Characteristics of Metabolically Obese Normal-Weight (MONW) Subjects. Appl Physiol Nutrition Metab (2007) 32(1):412. doi: 10.1139/h06-092

  • 40

    CotaBCSuhettLGLeiteNNPereiraPFRibeiroSAV. Franceschini SdCC. Cardiometabolic Risk and Health Behaviours in Adolescents With Normal-Weight Obesity: A Systematic Review. Public Health Nutr (2020) 24(5):870–81. doi: 10.1017/S1368980020004863

Summary

Keywords

normal weight obesity, central obesity, obesity, cardiometabolic, metabolic syndrome

Citation

Mohammadian Khonsari N, Khashayar P, Shahrestanaki E, Kelishadi R, Mohammadpoor Nami S, Heidari-Beni M, Esmaeili Abdar Z, Tabatabaei-Malazy O and Qorbani M (2022) Normal Weight Obesity and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis. Front. Endocrinol. 13:857930. doi: 10.3389/fendo.2022.857930

Received

19 January 2022

Accepted

14 February 2022

Published

24 March 2022

Volume

13 - 2022

Edited by

Luca Busetto, Università degli Studi di Padova, Italy

Reviewed by

Valeria Guglielmi, University of Rome Tor Vergata, Italy; Alexis Elias Malavazos, IRCCS San Donato Polyclinic, Italy

Updates

Copyright

*Correspondence: Mostafa Qorbani, ; Ozra Tabatabaei-Malazy,

This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics